Atwater Malick’s Amgen AMGN Stock Holding History

Atwater Malick’s Portfolio AMGN Stock Details AMGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-200	Closed	-$39K	–	44
2019 Q3	$39K	Buy	+200	New	+$38.4K	0.03%	80

Other funds holding AMGN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Atwater Malick's AMGN Position: Q4 2019 in Review

Atwater Malick sold out of Amgen (AMGN) in Q4 2019, closing a stake of 200 shares — an estimated $39K sold.

Atwater Malick first reported a position in AMGN in Q3 2019 and held it in 1 quarter. The position peaked at $39K in Q3 2019. 2,107 funds tracked by Wall St. Rank hold AMGN as of Q4 2019.

Atwater Malick reported no remaining Amgen position as of Q4 2019 after selling out during the quarter.
Atwater Malick sold 200 Amgen shares in Q4 2019, an estimated $39K.
Atwater Malick first reported a position in Amgen in Q3 2019 and held it in 1 quarter.
Atwater Malick's Amgen position peaked at $39K in Q3 2019.
2,107 funds tracked by Wall St. Rank held Amgen as of Q4 2019.

Based on Atwater Malick's 13F filing for Q4 2019, filed 7 Jan 2020.